STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Bladder cancer
Bladder cancer recurrence and progression
Risk stratification guidelines
STAG2
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
07
11
2020
revised:
20
01
2021
accepted:
04
02
2021
pubmed:
14
3
2021
medline:
24
12
2021
entrez:
13
3
2021
Statut:
ppublish
Résumé
Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC. STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models. STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC. STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted.
Identifiants
pubmed: 33712344
pii: S1078-1439(21)00069-7
doi: 10.1016/j.urolonc.2021.02.007
pmc: PMC8286298
mid: NIHMS1677853
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell Cycle Proteins
0
STAG2 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
438.e1-438.e9Subventions
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169345
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009686
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Tumour Biol. 2016 Aug;37(8):10279-86
pubmed: 26838030
Nat Genet. 2013 Dec;45(12):1459-63
pubmed: 24121792
Nat Genet. 2013 Dec;45(12):1464-9
pubmed: 24121791
Nat Commun. 2020 Sep 25;11(1):4858
pubmed: 32978382
BJU Int. 2000 Jan;85(1):48-53
pubmed: 10619945
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
J Urol. 2012 Jan;187(1):310-4
pubmed: 22099989
Nat Genet. 2013 Dec;45(12):1428-30
pubmed: 24121789
Am J Pathol. 2001 Jun;158(6):1955-9
pubmed: 11395371
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
Eur Urol. 2008 Oct;54(4):835-43
pubmed: 18166262
Curr Opin Urol. 2014 Sep;24(5):487-91
pubmed: 24887047
Urol Clin North Am. 2013 May;40(2):261-9
pubmed: 23540783
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Am J Pathol. 2012 May;180(5):1824-34
pubmed: 22449953
J Urol. 2003 Apr;169(4):1291-4
pubmed: 12629345
Nat Rev Cancer. 2020 Sep;20(9):504-515
pubmed: 32514055
Hum Mol Genet. 2014 Apr 15;23(8):1964-74
pubmed: 24270882
Clin Cancer Res. 2018 Sep 1;24(17):4145-4153
pubmed: 29954776
Clin Genitourin Cancer. 2018 Oct;16(5):e985-e992
pubmed: 29884516